FCRL5 and neoplasm: FCRL5/IL-15 CAR-T cells promoted a shift towards the TCM phenotype while reducing PD-1 exhaustion, which may facilitate more durable and potent anti-tumor responses, thus potentially overcoming the limitations of BCMA-targeted therapy.